

## Product Information

# Mucin from porcine stomach

Type II

**M2378**

## Product Description

CAS Registry Number: 84062-64-4

Mucins are highly glycosylated proteins that occur in mucus and the mucous membranes of animals and humans. The principal glycoprotein component of mucus, mucins are associated with such organs as the abdomen and the stomach. Their high degree of glycosylation renders mucins highly stable to digestion in acidic *in vivo* environments such as gastric mucosa.

Polymeric mucin has been estimated to have a molecular mass of ~4,000-5,500 kDa.<sup>1,2</sup> The molecular mass of mucin monomer has been estimated at ~640 kDa.<sup>2</sup> Estimates of porcine mucin composition include a carbohydrate portion of 80-84%, and a protein portion of 16-20%.<sup>1-3</sup> The peptide backbone of mucin is notably rich in Pro, Ser, and Thr residues, which comprise ~43% of the amino acid composition of the mucin peptide backbone. Cys residues are prevalent in the non-glycosylated portions of mucin, and allow for crosslinking of mucin monomers to create highly complex polymers.

In porcine mucin, *O*-glycosylation occurs particularly at serine and threonine residues. The more prevalent *O*-linked glycans in porcine mucin include:<sup>3</sup>

- *N*-acetylgalactosamine
- *N*-acetylglucosamine
- Fucose
- Galactose
- *N*-acetylneuraminic acid (sialic acid)

Several studies have investigated the structural properties of porcine gastric mucin, and proposed various structural models.<sup>4-6</sup> Several theses<sup>7-12</sup> and dissertations<sup>13-23</sup> have cited use of product M2378 in their protocols.

This product has bound sialic acid content in the range of ≤1.2%, measured as *N*-acetylneuraminic acid. This product is not sterile.

## Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Procedure

A general procedure for sterilizing mucin has been published,<sup>24</sup> as follows:

1. Place dry powdered mucin in a flask.
2. Cover the mucin with 95% ethanol.
3. Heat the covered mucin at 70 °C for 24 hours.
4. Evaporate the alcohol to recover the mucin.

However, we have not tested this procedure ourselves.

## Storage/Stability

Store the product at 2-8 °C.

## References

1. Fogg, F.J.J. *et al.*, *Biochem. J.*, **316(Pt 3)**, 937-942 (1996).
2. Schömig, V.J. *et al.*, *RSC Adv.*, **6**, 44932-44943 (2016).
3. Libao-Mercado, A.J., and de Lange, C.F.M., *Livestock Sci.*, **109(1-3)**, 141-144 (2007).
4. Perez-Vilar, J., and Hill, R.L., *J. Biol. Chem.*, **274(35)**, 31751-31754 (1999).
5. Di Cola, E. *et al.*, *Biomacromolecules*, **9(11)**, 3216-3222 (2008).
6. Veluraja, K. *et al.*, *Biochem. Biophys. Res. Comm.*, **406(94)**, 570-573 (2011).
7. Waldbrook, Matthew George, "In vivo efficacy of novel antibacterial and immunomodulatory synthetic peptides". University of British Columbia, M.Sc. thesis, p. 14 (2008).

8. Jyssum, Kari, "Particle Mobility in Mucus Role of Surface Interactions and Use of G-blocks". Norwegian University of Science and Technology, M.Sc. thesis, p. 17 (2012).
9. Moser, Sydney Elizabeth, "The effect of individual milk proteins on bioaccessibility of green tea flavan-3-ols". Purdue University, M.S. thesis, p. 54 (2013).
10. Brownlie, Emma J.E., "Using *In Vitro* Approaches to Study Relationships Between Key Members of the Murine Gut Microbiota". University of Toronto, M.Sc. thesis, p. 17 (2019).
11. Franceus, Maksine, "*In vitro* study of the growth and functionality of gut bacteria under the influence of dietary emulsifiers". Universiteit Gent, M.Sc. thesis, p. 123 (2019).
12. Dupont, Haley A., "Examining abiotic and biotic factors influencing bacterial and host interactions in the female reproductive tract". McMaster University, M.Sc. thesis, p. 40 (2020).
13. Jowiya, C.W.J., "The Response of *Campylobacter jejuni* to Pancreatic Enzymes". University College London, Ph.D. dissertation, p. 38 (2013).
14. Kallapura Sheshagiri, Gopala Krishna, "Comparison of Potential Salmonella Portals of Entry and Tissue Distribution Following Challenge of Poultry". University of Arkansas, Fayetteville, Ph.D. dissertation, p. 118 (2013).
15. Cao, Yanlu, "Function and regulation of the polysaccharide utilization locus, *Don*, in the gut symbiont *Bacteroides Fragilis*". East Carolina University, Ph.D. dissertation, pp. 24, 84 (2014).
16. Kaliki, Srimahitha, "Characterization of Biological Hydrogel Barriers". University of Texas at Austin, Ph.D. dissertation, pp. 27, 45 (2014).
17. Alves, Diana, "Development and characterisation of a responsive polyvalent bacteriophage therapeutic". University of Bath, Ph.D. dissertation, p. 75 (2015).
18. Vassallo, Joanne, "The bioavailability and biological effects of nanomaterials towards *Escherichia coli*: with reference to the soil environment". University of Plymouth, Ph.D. dissertation, p. 220 (2018).
19. Rozenbaum, René Theodoor, "Antimicrobial and nanoparticle penetration and killing in infectious biofilms". Rijksuniversiteit Groningen, Ph.D. dissertation, p. 19 (2019).
20. Winkeljann, Benjamin, "Functional biomacromolecules on medical polymer surfaces". Technischen Universität München, Dr. ing. dissertation, p. 122 (2020).
21. Hayes, Micaela Danielle, "Influence of Spinach Genotype and Processing Method on Chlorophyll and Carotenoid Bioaccessibility in the Upper and Lower Gastrointestinal Tract". North Carolina State University, Ph.D. dissertation, p. 113 (2021).
22. Zhang, Xiao, "Magnetic Gradient-Based Magnetic Tweezer System for 3D and Swarm Control of Microswimmer". Southern Methodist University, Ph.D. dissertation, p. 11 (2021).
23. Turcanu, Mihnea Vlad, "Progress towards ultrasound-mediated targeted drug delivery in the small intestine". University of Glasgow, Ph.D. dissertation, p. 44 (2022).
24. Yeung, A.T.Y. *et al.*, *MBio*, **3(3)**, e00073-12 (2012).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

## Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://SigmaAldrich.com/techservice).

## Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://SigmaAldrich.com/terms).

## Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://SigmaAldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.  
© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

M2378pis Rev 04/22 GCY,MAM

**MILLIPORE  
SIGMA**